A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

To be considered for this study, you would need to have advanced kidney cancer (renal cell carcinoma) that doctors can't remove with surgery or radiation, or cancer that has spread. This could be either a common type (clear cell RCC) or a less common type (non-clear cell RCC) for the initial part of the study.

Generally, you shouldn't have had previous treatment for advanced kidney cancer, though there are a few exceptions. For example, if you had treatment after surgery that wasn't designed to block specific growth factors, or if new cancer appeared more than six months after that treatment. Also, if you're in certain parts of the study, you shouldn't have previously received drugs like ipilimumab or cabozantinib.

It's important that your cancer can be measured by doctors, and you shouldn't have untreated cancer that has spread to your brain or spinal cord. Other health conditions, like serious heart problems, active lung disease, or conditions requiring high doses of certain medications that suppress the immune system, might mean you're not suitable for this study.

If you decide to take part in this study, you'll receive one of the study treatments, which could be Pumitamig on its own, or Pumitamig combined with either Ipilimumab or Cabozantinib. You would have regular visits to the clinic for medical examinations, blood tests, and scans (like CT scans or MRI scans) to see how the treatment is working and monitor your health. You might also need to answer questionnaires about how you're feeling. The exact number of visits, tests, and how long you'd be on the treatment can vary, but generally, you'd continue treatment as long as it's benefiting you and you're not experiencing significant side effects. There might also be a follow-up period after you stop treatment to monitor your health.